Point72 Asset Management
AVIR icon

Point72 Asset Management’s Atea Pharmaceuticals AVIR Stock Holding History

Point72 Asset Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$643K Buy
119,553
+55,648
+87% +$256K ﹤0.01% 3009
2025
Q4 		$228K Buy
+63,905
New +$203K ﹤0.01% 3588
2023
Q3 		– Sell
-9
Closed -$34 – 2463
2023
Q2 		$34 Sell
9
-36,673
-100% -$137K ﹤0.01% 2085
2023
Q1 		$123K Buy
+36,682
New +$149K ﹤0.01% 1591
2021
Q4 		– Sell
-332,200
Closed -$11.6M – 1084
2021
Q3 		$11.6M Buy
+332,200
New +$9.21M 0.05% 449

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Point72 Asset Management's AVIR Position: Q1 2026 in Review

Point72 Asset Management increased its Atea Pharmaceuticals (AVIR) stake by 87% in Q1 2026, buying an estimated $256K and bringing the position to 119,553 shares worth $643K. The position accounts for ﹤0.01% of the portfolio, ranked #3009.

Point72 Asset Management first reported a position in AVIR in Q3 2021 and has held it in 5 quarters since. The position peaked at $11.6M in Q3 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Point72 Asset Management held 119,553 shares of Atea Pharmaceuticals worth $643K as of Q1 2026.
  • Point72 Asset Management bought 55,648 Atea Pharmaceuticals shares in Q1 2026, an estimated $256K.
  • Atea Pharmaceuticals made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #3009 holding.
  • Point72 Asset Management first reported a position in Atea Pharmaceuticals in Q3 2021 and has held it in 5 quarters since.
  • Point72 Asset Management's Atea Pharmaceuticals position peaked at $11.6M in Q3 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.